Craig Tooman

Executive Vice President of Finance, Chief Financial Officer

Print

Craig Tooman

Craig Tooman has served as Enzon’s  executive vice president of finance and chief financial officer since, 2005. In this role, he is responsible for all financial aspects of Enzon, in addition to the Company’s investor relations, public relations, and  strategic planning functions. Mr. Tooman joined Enzon in January 2005 as the Company’s executive vice president of strategic planning and corporate communications.

Mr. Tooman has nearly 20 years of industry experience, having worked extensively in diverse pharmaceutical positions including investor communications, strategic planning, finance, marketing, and sales. Prior to joining Enzon, he served as senior vice president of strategic planning and corporate communications of ILEX Oncology, Inc, which was acquired by Genzyme in December 2004.

While at ILEX, Mr. Tooman managed the formation of ILEX’s first comprehensive strategic  plan and the restructuring of the company’s clinical development activities to drive the company’s transformation from a drug development contract research organization into a product-driven pharmaceutical company. Mr. Tooman was also responsible for managing ILEX’s investment banking relationships, including playing a critical role in the merger of ILEX and Genzyme, a $1 billion transaction.

Before joining ILEX, Mr. Tooman worked at Pharmacia Corporation where he progressed  through positions of increasing responsibility in investor relations, including vice president of investor relations. In this role, he was responsible for global investor relations activities and spearheaded communications with the financial community on the Pharmacia and Upjohn/Monsanto merger. Additionally, under his leadership the Investor Relations unit of Pharmacia won four of the largest awards of distinction in Investor and Public Relations. He has also held various management positions in Europe and Japan.

Mr. Tooman received his B.A. in economics from Kalamazoo College and an M.B.A. in finance from the University of Chicago.

Search
(ENZN) NASDAQ
Last Trade9.30
Change(%)price+0.01
Volume829038
News
  • 09-10-2009

    Enzon to Present at NewsMakers...

    Enzon to Present at NewsMakers in the Biotech Industry Conference

    click here for more information

  • 07-27-2009

    Enzon to Release Second Quarte...

    Enzon to Release Second Quarter 2009 Earnings on Tuesday, August 4, 2009; Conference Call and Webcast to Follow

    click here for more information

  • 07-27-2009

    Enzon to Present at BMO Focus...

    Enzon to Present at BMO Focus on Healthcare Conference

    click here for more information

  • 07-23-2009

    Enzon Enhances Governance with...

    Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director

    click here for more information

  • 03-19-2009

    Enzon Treats Patients with Sur...

    Enzon Treats Patients with Survivin Antagonist
    -- Enzon's compound advances into the clinic for patients with solid tumors and lymphomas--

    click here for more information

  • 03-16-2009

    Enzon to Present at 29th Annua...

    Enzon to Present at 29th Annual Cowen and Company Conference

    click here for more information

  • 08-06-2008

    Enzon Reports Solid Second Qua...

    Enzon Reports Solid Second Quarter 2008 Results
    -- Product revenues increase 17% --

    click here for more information

  • 12-08-2008

    Enzon Pharmaceuticals Commence...

    Enzon Pharmaceuticals Commences Tender Offer For a Portion of its Debt

    click here for more information

  • 07-23-2009

    Enzon Enhances Governance with...

    Enzon Enhances Governance with the Addition of a New Non-Executive Chairman and New Independent Director

    click here for more information

  • 06-01-2009

    Enzon Presents Clinical Data f...

    Enzon Presents Clinical Data from HIF-1 Alpha Antagonist Study at ASCO
    -- First specific HIF-1a inhibitor is well tolerated with early signs of clinical benefit--

    click here for more information

  • 04-23-2009

    Enzon's Board of Directors Rea...

    Enzon's Board of Directors Reaffirms Support of its Chairman and CEO

    click here for more information

  • 02-10-2009

    Enzon Announces IND Acceptance...

    Enzon Announces IND Acceptance for its Survivin Antagonist
    -- Phase I study to open for patients with solid tumors--

    click here for more information